10x Genomics (TXG) Total Liabilities (2018 - 2026)

10x Genomics (TXG) has 9 years of Total Liabilities data on file, last reported at $201.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 2.51% year-over-year to $201.4 million; the trailing twelve-month figure through Mar 2026 stood at $201.4 million (up 2.51% YoY), and the FY2025 full-year result was $245.0 million, up 17.52% from the prior year.
• Total Liabilities eased to $201.4 million in Q1 2026, from $245.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $245.0 million in Q4 2025 to a low of $196.3 million in Q2 2023.
• A 5-year average of $212.9 million and a median of $208.5 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities slipped 9.97% in 2023 and advanced 17.52% in 2025, its largest moves.
• Tracing TXG's Total Liabilities over 5 years: stood at $223.2 million in 2022, then grew by 0.39% to $224.1 million in 2023, then slipped by 6.96% to $208.5 million in 2024, then climbed by 17.52% to $245.0 million in 2025, then dropped by 17.79% to $201.4 million in 2026.
• Business Quant data shows TXG's Total Liabilities at $201.4 million in Q1 2026, $245.0 million in Q4 2025, and $242.2 million in Q3 2025.